Article | Published:

Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma

Abstract

Human β-defensins contain an oncolytic motif that binds to tumor cell membranes and mediate permeabilization, rapid induction of cytolysis, and apoptosis. Previous studies have indicated that a fragment of the mature human β-defensin-1 (HBD1) peptide (DF) has antitumor properties. While targeted drug treatments using fusion proteins have been shown to increase drug efficacy, this phenomenon has not been studied for this defensin. Thus, in this study, we designed and prepared a fusion protein containing this HBD1 fragment and an epidermal growth factor receptor (EGFR)-targeting oligopeptide (Ec) as well as lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, which consists of an apoprotein (LDP) and a highly active enediyne (AE). The fusion protein (Ec-LDP-DF) and its enediyne-integrated fusion protein (Ec-LDP(AE)-DF) were then purified and used to treat lung carcinoma cells in culture as well as lung carcinoma xenograft mouse models. The multifunctional fusion protein Ec-LDP-DF was shown to effectively bind to EGFR-expressing tumor cells. Furthermore, the enediyne-energized Ec-LDP(AE)-DF analog exhibited extremely potent cytotoxicity in NSCLC cell lines and an IC50 less than 10−10 mol/L. Ec-LDP(AE)-DF also significantly inhibited the growth of human carcinoma A549 and H460 xenografts in athymic mice at well-tolerated doses. Treatment resulted in cell cycle arrest and apoptosis in a dose-dependent manner. EGF-stimulated EGFR phosphorylation was also abolished by Ec-LDP(AE)-DF. In summary, our understanding of the role of defensins in cancer development and progression is continually expanding, and Ec-LDP(AE)-DF is a promising cancer cell-targeting agent for NSCLC.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J, et al. Defensins: natural component of human innate immunity. Hum Immunol. 2013;74:1069–79.

  2. 2.

    Ulm H, Wilmes M, Shai Y, Sahl HG. Antimicrobial host defensins—specific antibiotic activities and innate defense modulation. Front Immunol. 2012;3:249.

  3. 3.

    Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286:525–8.

  4. 4.

    Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci. 2005;62:784–90.

  5. 5.

    Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics. 2009;72:918–27.

  6. 6.

    Prado-Montes DOE. Human beta-defensin 1: a restless warrior against allergies, infections and cancer. Int J Biochem Cell Biol. 2010;42:800–4.

  7. 7.

    Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, He J, et al. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 2006;66:8542–9.

  8. 8.

    Phan TK, Lay FT, Poon IK, Hinds MG, Kvansakul M, Hulett MD. Human beta-defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation. Oncotarget. 2016;7:2054–69.

  9. 9.

    Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem. 2008;8:123–31.

  10. 10.

    Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, et al. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci. 2012;47:781–9.

  11. 11.

    Guo XF, Zhu XF, Shang Y, Zhang SH, Zhen YS. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res. 2010;16:2085–94.

  12. 12.

    Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q, et al. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett. 2010;295:124–33.

  13. 13.

    Guo XF, Zhu XF, Cao HY, Zhong GS, Li L, Deng BG, et al. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Oncotarget. 2017;8:27286–99.

  14. 14.

    Sun YW, Xu J, Zhou J, Liu WJ. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 2018;9:5459–72.

  15. 15.

    Liu WJ, Liu XJ, Li L, Li Y, Zhang SH, Zhen YS. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation. Cancer Immunol Immunother. 2014;63:1261–72.

  16. 16.

    Liu W-J, Liu X-J, Xu J, Li L, Li Y, Zhang S-H, et al. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis. Acta Pharmacologica Sinica. 2018;1–10. https://doi.org/10.1038/s41401-018-0069-8.

  17. 17.

    Xu J, Liu XJ, Li L, Zhang SH, Li Y, Gao RJ, et al. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget. 2015;6:26322–34.

  18. 18.

    Xu J, Du Y, Liu XJ, Zhu BY, Zhang SH, Li L, et al. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacol Res. 2017;126:66–76.

  19. 19.

    Wang X, Qiao X, Shang Y, Zhang S, Li Y, He H, et al. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo. Amino Acids. 2017;49:931–41.

  20. 20.

    Du Y, Shang BY, Sheng WJ, Zhang SH, Li Y, Miao QF, et al. A recombinantly tailored beta-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Oncotarget. 2016;7:58418–34.

  21. 21.

    Suarez-Carmona M, Hubert P, Delvenne P, Herfs M. Defensins: “Simple” antimicrobial peptides or broad-spectrum molecules? Cytokine Growth Factor Rev. 2015;26:361–70.

  22. 22.

    Zhuravel OV, Gerashchenko OL, Khetsuriani MR, Soldatkina MA, Pogrebnoy PV. Expression of human beta-defensins-1–4 in thyroid cancer cells and new insight on biologic activity of hBD-2 in vitro. Exp Oncol. 2014;36:174–8.

  23. 23.

    Zhang M, Qiu Z, Li Y, Yang Y, Zhang Q, Xiang Q, et al. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study. Appl Microbiol Biotechnol. 2013;97:3913–23.

  24. 24.

    Wilmes M, Sahl HG. Defensin-based anti-infective strategies. Int J Med Microbiol. 2014;304:93–9.

  25. 25.

    Semlali A, Al Amiri A, Azzi A, Al Shahrani O, Arafah M, Kohailan M, et al. Expression and new exon mutations of the human beta defensins and their association on colon cancer development. PLoS One. 2015;10:e126868.

  26. 26.

    Kamino Y, Kurashige Y, Uehara O, Sato J, Nishimura M, Yoshida K, et al. HBD-2 is downregulated in oral carcinoma cells by DNA hypermethylation, and increased expression of hBD-2 by DNA demethylation and gene transfection inhibits cell proliferation and invasion. Oncol Rep. 2014;32:462–8.

  27. 27.

    Baxter AA, Poon IK, Hulett MD. The plant defensin NaD1 induces tumor cell death via a non-apoptotic, membranolytic process. Cell Death Discov. 2017;3:16102.

  28. 28.

    Xu J, Du Y, Liu W-J, Li L, Li Y, Wang X-F, et al. Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. Taylor & Francis 2017. https://doi.org/10.1080/10717544.2017.1410261.

  29. 29.

    Roskoski RJ. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319:1–11.

  30. 30.

    Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989;58:287–92.

  31. 31.

    Wen R, Umeano AC, Dhar S. Accessing mitochondrial targets using NanoCargos. In: Intracellular delivery III. Springer; 2016. p. 229–54.

  32. 32.

    Guo XF, Zhu XF, Yang WC, Zhang SH, Zhen YS. An EGFR/HER2-bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer. PLoS ONE. 2014;9:e92986.

  33. 33.

    Janthur WD, Cantoni N, Mamot C. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci. 2012;13:16020–45.

  34. 34.

    Pathak RK, Wen R, Kolishetti N, Dhar S. A prodrug of two approved drugs, cisplatin and chlorambucil, for chemo war against cancer. Mol Cancer Ther. 2017;16:625–36.

  35. 35.

    Wen R, Banik B, Pathak RK, Kumar A, Kolishetti N, Dhar S. Nanotechnology inspired tools for mitochondrial dysfunction related diseases. Adv Drug Deliv Rev. 2016;99:52–69.

Download references

Acknowledgements

This study was financially supported by the High-Tech Research and Development Program of Shandong Province (2014GSF118022); the National Natural Science Foundation of China (Nos. 81502691 and 81573246); the China Postdoctoral Science Foundation Grant (2017M622188); and the Natural Science Foundation of Shandong Province (ZR2015HM040).

Author information

Correspondence to Hui Zhu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Supplementary figure 1

Supplementary figure 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6